The therapeutic goals for ulcerative colitis have changed from the treatment of symptoms towards mucosal healing, with the aim of modifying the natural history of the disease and preserving gut functiona lity. The concept of deep remission in ulcerative colitis, which includes symptomatic and endoscopic remission, emerged a decade ago when several studies clearly showed the importance of looking beyond symptoms and achieving and maintaining endoscopic healing 1 . Endoscopic healing (absence of inflammatory lesions in segments of the colon at endoscopy) is associated with improved short-term and long-term outcomes 1 .
Histological remission is being recognized as a major therapeutic goal and endpoint for ulcerative colitis as histological alterations are often found in the presence of macroscopically normal mucosa seen at endo scopy 2 . Evidence indicates that histological remission is a target distinct from endoscopic healing in ulcerative colitis and is associated with lower risks of hospitalizations, colectomy and colorectal cancer than endoscopic healing 1 . The combination of symptomatic remission and endoscopic healing was proposed as a therapeutic goal of treat-to-target strategies in IBD by the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) committee 1 , whereas histological healing did not reach a consensus during the STRIDE voting process, mainly due to the lack of intervention trials 1 . However, STRIDE guidelines were developed for routine practice and not for clinical trials.
The treatment goal evolution in IBD has paralleled other immune-mediated diseases including skin disorders such as psoriasis, in which clinical ambition has peaked with the new concept of disease clearance 3 . Psoriasis is a lifelong chronic inflammatory skin disease that shares similarities with IBD in terms of pathogenesis, disease burden and medications 3 . Psoriasis treatment guidelines consider a therapy to be effective when the Psoriasis Area Severity Index (PASI) improves by at least 75% (PASI 75) 4 . However, studies have shown that residual disease activity is associated with low quality of life (QOL) 4 . Total skin clearance and reduction of symptoms are now considered as treatment goals 4 . Patients that responded to treatment with total skin clearance (PASI 100) demonstrated minimal or no impairment in dermatology-related (QOL) factors and did not experience symptoms of psoriasis 4 . Several clinical trials also showed that disease clearance in psoriasis is achievable. A study with secukinumab revealed that achieving a PASI response of 90 compared with 75-89 correlates with better QOL at week 12 (REF. 4 ). In the UNCOVER-1 study, 35.3% of patients treated with ixekizumab reached PASI 100 at week 12 and 80% achieved PASI 75 (REF. 5 ). Overall, a PASI 100 response represents the ultimate therapeutic goal in psoriasis, but no current treatment can achieve it in >50% of patients.
Here, we introduce a new concept in ulcerative colitis termed disease clearance, which defines a state of deep and complete remission. We propose that the disease clearance definition includes symptomatic remission (patient reported outcomes) and mucosal healing (endos copic and histological healing) ( Fig. 1 ). Notably, clinical remission in ulcerative colitis corresponds to symptomatic remission plus endoscopic improvement according to Mayo score 6 , whereas mucosal healing in clinical trials now includes both endoscopic improvement and histological healing according to the FDA. However, few studies have examined composite end points that include both symptomatic remission and mucosal healing in ulcerative colitis. Data from clinical trials in ulcerative colitis have reported low rates of combined clinical plus endoscopic healing or histo logical plus endoscopic healing; therefore, rates of disease clearance are expected to be even lower.
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in the treatment algorithm and drug improvement are still needed. Supplementary Table 1 summarizes clinical trial data on rates of histological remission presented at the 2018 and 2019 European Crohn's and Colitis Organisation meetings. Across four studies with four different drugs, histological remission was achieved in 19.5-43.9% of patients. In another trial, 17.6% of patients treated with adalimumab achieved histological remission at week 8; notably, achievement of histological and endoscopic healing required higher levels of adalimumab than previously described for endoscopic remission 8 . More encouraging data come from the GEMINI study, which demonstrated that vedolizumab induces histological healing in >50% of patients with mucosal healing 9 .
Most patients with ulcerative colitis do not achieve composite clinical and endoscopic remission in real-world practice. Data from a multicentre retrospective Australian study including 246 patients with ulcerative colitis showed that: clinical remission was achieved in 61% of patients, of whom 57% were also in endoscopic remission (Mayo score ≤1); and 35% of patients were in combined clinical and endoscopic remission, of whom 46% were also in histological remission and only 16% of patients were in combined clinical, endoscopic, and histological remission 10 . Taken together, clinical trials plus real-world practice show that disease clearance is achievable in ulcerative colitis but the rates of patients achieving this goal are lower than in psoriasis. Personalized medicine based on the stratification of patients according to risk factors, and selection of drugs based on patient characteristics might help increase rates of disease clearance in the future.
Ulcerative colitis is now considered a progressive disease given the risks of proximal extension, strictures, pseudopolyposis, gut dysmotility, anorectal dysfunction, colectomy, hospitalization, colorectal cancer and disability. Thus, the concept of disease clearance in ulcerative colitis is attractive. Observational studies and data from phase I and phase II clinical trials have shown encouraging data supporting the association of disease clearance with improved outcomes, and treat-to-clear could be the ultimate goal in the treatment of ulcerative colitis 1, 2 . Whether sustained clearance has the potential for disease modification in ulcerative colitis will require dedicated intervention trials. In conclusion, available evidence shows that disease clearance is achievable in ulcerative colitis with current drugs, but achieving it will raise the bar in terms of therapeutic objectives, leading to an increase of drug failure during clinical trials and the need to switch or swap therapy to reach high rates of histological remission and therefore disease clearance. Also, many clinicians continue to manage symptoms of disease and few follow the treat-to-target approach with mucosal healing as the target in ulcerative colitis. Hence, the implementation of these strategies, with disease clearance being the ultimate therapeutic goal in these patients, will be our main challenge for the next decade. Disease clearance might enable de-escalation or exit strategies from drugs in ulcerative colitis. This concept will be explored in the ongoing IN-TARGET multicentre trial from the GETAID group which will evaluate histological remission at week 54 and 108 as secondary objectives in patients with moderate to severe ulcerative colitis treated with golimumab. Last but not least, the definition of disease clearance in ulcerative colitis will need a standardized and validated definition and will possibly evolve beyond histological healing to molecular healing with restoration of specific molecular pathways involved in the aetiopathogenesis of the disease using drugs targeting patient-specific pathways 1 .
